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Abstract: Pharmacogenomics (i.e., the application of genetic information in predicting an
individual’s response to drug therapy) plays an increasingly important role in drug develop-
ment and decision-making regarding precision medicine. This has been shown to reduce the
risk of adverse events and improve patient health-care outcomes through targeted therapies
and dosing. As the field of pharmacogenomics rapidly evolves, the role of pharmacists in the
education, implementation, and research applications of pharmacogenomics is becoming
increasingly recognized. This paper aims to provide an overview and current perspectives
of pharmacogenomics in contemporary clinical pharmacy practice and to discuss the future
directions on advancing pharmacogenomics education, application, and research in pharmacy
practice.
Keywords: pharmacogenomics, pharmacy practice, precision medicine, pharmacist role
Introduction
Precision medicine refers to the use of genetic, environmental, lifestyle, and other
unique patient or disease characteristics to guide drug selection and dosage. It is also
highlighted as personalized medicine or precision health. Pharmacogenetics/pharma-
cogenomics (PGX) as a discipline is part of precision medicine and personalized
healthcare. PGX uses genetic information to predict subject’s response to a medica-
tion (i.e., responders vs nonresponders to a medication), and to determine patients
likely to experience adverse events of the medication, and the optimal drug dose.1
It was not until the completion of the human genome project that major advance-
ments have been achieved in PGX and its role in improving the quality of health care.2
Over the last two decades, PGX started to get integrated in drug development and
clinical treatment decisions.3 Drug manufacturers and other pharmaceutical research
laboratories have begun to screen different molecules to determine if they undergo
metabolism through highly polymorphic pathways before proceeding to full-blown
efficacy and safety evaluations.4 In addition, drug regulatory agencies have developed
recommendations and guidelines to promote and regulate the clinical application of
PGX.5,6 The US’ Food and Drug Administration (FDA) currently endorses a broad list
of approved drug labels carrying PGX-related information and recommendations.7
However, the integration and clinical application of PGX into clinical practice is not
without challenges. For example, health-care practitioners’ knowledge and experience
in PGX application has been shown to remain lagging behind. In recent years, accred-
itation and educational councils as well as professional pharmacy organizations have
begun advocating for PGX education in colleges’ curricula.8 Another important
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challenge that is still facing the implementation and applica-
tion of PGX in clinical practice is the limited availability of
rapid genetic tests and the inability of health-care providers
to use these tests.9,10 Other barriers include perceived lack of
adequate evidence for the clinical utility of PGX test; lack of
access to the test; data security and protection of personal
information; cultural and religious belief; and limited
resources.11–13 Examples of required resources may include
financial resources, infrastructure, qualified staff to provide
the PGX service, and proper platform to store and interpret
the genetic data.
Pharmacist’s role in patient care has evolved and become
the cornerstone in different specialties such as pharmacoki-
netics, anticoagulation, antimicrobial stewardship, and med-
ication therapy management (MTM).14–17 The knowledge
and skills of clinical pharmacists in pharmacokinetics and
pharmacodynamics of drugs give them an advantage to take
the lead and provide clinical services in the evolving area of
PGX. In a statement draft on the pharmacist’s role in clinical
PGX, the American Society of Health-System Pharmacists
(ASHP) highlighted the ability of clinical pharmacist to lead
interprofessional efforts to develop guidelines and protocols
and to initiate PGX services.16 Different institutions have
already initiated pharmacist-managed clinical PGX
programs.16,18 Therefore, the potential role of pharmacist in
the integration of PGXs into pharmacy practice is becoming
increasingly important. The purpose of this paper is to pro-
vide an overview and current perspectives of PGX in con-
temporary clinical pharmacy practice. The paper also
discusses the future directions on advancing PGX education,
application, and research in pharmacy practice.
Pharmacist Role In Providing
Pharmacogenomics Service
As PGX continues to evolve, the emerging discipline will
play a significant role in drug development and treatment
decision-making in clinical practice. Pharmacists currently
lead PGX services that tailor patients’ drug therapy using
genetic information.19,20 In their work with pharmaceutical
manufacturers, FDA, and other regulatory authorities, phar-
macists play a major role to incorporate PGX data and apply
this information into the drug development, drug labeling,
and approval processes.21 With these advancements, new
innovations and processes are needed to effectively integrate
these PGX data into clinical practice.22
In parallel, the role of pharmacist in collaborative care
through MTM and other platforms has equally emerged in
the last few decades.16,23 The potential role of the pharma-
cists in integrating PGX data into clinical practice for the
purpose of personalizing medicines and improving patient
care outcomes is becoming increasingly important.16,23,24
This will require certain action plans, including, but not
limited to, engagement with key stakeholders, establishing
appropriate electronic health record (EHR) infrastructure,
connectivity into the EHR, and demonstrating the evidence
of benefit and value for pharmacist-involved PGX
service.25 In addition, understanding the potential barriers
and system limitations to the implementation of PGX
service and establishing effective infrastructure for the
service will be necessary for successful implementation
and for PGX to achieve its full potential.22,26
Pharmacy profession has started defining its role and
approaches to effectively integrate this evolving field into
clinical pharmacy practice through professional pharmacy
organizations. One strategy for implementation of PGX in
pharmacy practice is through MTM, a service that is
provided in diverse care settings and that is proven to
optimize therapeutic outcomes for individual patients.27
Therefore, MTM provides a unique opportunity for phar-
macists to integrate PGX into clinical practice and to
actively engage in collecting or ordering, interpreting,
reporting, and utilizing PGX data to improve patient care
outcomes including safety, quality, and effectiveness of
medication therapy.24
Although experts and researchers have proposed the
integration of PGX testing into MTM to improve treatment
outcomes and to reduce the risk of adverse events, little
research has been done to demonstrate the benefit or value
of this service integration.27–29 One pilot study aiming to
assess the feasibility and satisfaction of patients with
MTM plus PGX testing service in a cardiology outpatient
clinic in the USA found that PGX testing incorporated into
a pharmacist-delivered MTM service was feasible and that
patients were very satisfied with the service.30 Given the
apparent lack of sufficient evidence of the effectiveness of
PGX delivery models in MTM, this study has provided a
preliminary evidence of benefit regarding the incorpora-
tion of PGX in MTM service. Haga et al have discussed
the challenges to the integration and delivery of PGX
testing in MTM services including, but not limited to,
the timing of and access to PGX testing, extended MTM
sessions, information technology and limited access to
EHR, training/competence and workforce, and issues sur-
rounding reimbursement of MTM services.30
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Pharmacists are uniquely positioned to guide optimal
drug selection and dosing based on PGX testing.16
Therefore, pharmacists have an essential responsibility to
make sure that testing is done when appropriate and that
the results are utilized to optimize patients’ medication
therapy.24 This implies that pharmacists share responsibil-
ity with other health-care providers such as physicians,
laboratory scientists, and genetic counselors. The ASHP
has published a position statement in 2015 highlighting the
responsibilities and functions of pharmacists in PGX.31
According to the ASHP position statement, any clinical
PGX service should include the following responsibilities:
(1) promoting rational and routine use of PGX testing; (2)
interpreting test results and communicating with patients
and other health-care professionals; (3) optimization of
medication therapy based on test results; (4) providing
information on clinical application of PGX to health-care
professionals, patients, and the public; and (5) contributing
in PGXs research and other platforms concerned with the
integration and application of PGX into clinical practice.
The statement further provided recommendations for phar-
macists’ functions in PGX. The functions depend on the
level of training, education, experience, and the practice
setting. For example, it is recommended that all pharma-
cists should have a basic understanding of PGX, which
should enable them to undertake some basic PGX func-
tions, while pharmacists having specialized or advanced
training, education, or experience in PGX should assume
additional functions. For more information on pharma-
cists’ responsibilities and functions for PGX, please refer
to the ASHP position statement on the pharmacist’s role in
clinical PGX.31
Similarly, the American College of Clinical Pharmacy
(ACCP) White Paper on integrating PGX into clinical
pharmacy practice has articulated the real-world clinical
applications of precision pharmacotherapy with a focus on
the evolving field of clinical PGX.25 This paper stresses
that clinical pharmacists play an instrumental role in the
implementation, education, and research applications of
PGX. It further provides recommendations on how the
ACCP can advance the implementation, education, and
research application of clinical PGX.
Overall, pharmacists can play an invaluable role in
leading the implementation of PGX in clinical practice
and to lead the judicious use of PGX data for improving
outcomes of care in health-care institutions.16,25,26
Academic pharmacy programs and professional pharmacy
bodies such as ACCP and ASHP are well positioned to
implement curricula changes and to advance pharmacy
students’ and pharmacists’ knowledge and skills in clinical
PGX and precision pharmacotherapy.16,22,23,25,26,31
Successful Examples Of Clinical
Implementation Of Pharmacogenetic
Testing In Pharmacy Practice
PGX has been widely studied in cardiovascular medicine.
Clopidogrel and warfarin were among the most successful
drugs that showed effect of genetic variants on clinical
outcomes associated with these drugs.
Clopidogrel
Clopidogrel is the most widely used P2Y12 inhibitor world-
wide especially in the prevention of thrombotic events in
patients with acute coronary syndrome (ACS) and/or
stroke.32–34 Nevertheless, not all patients respond to clopi-
dogrel therapy adequately. This interpatient variability may
compromise both efficacy and safety.35 Clopidogrel is a
thienopyridine prodrug that requires hepatic biotransforma-
tion to form an active metabolite that selectively and irre-
versibly inhibits the purinergic P2Y12 receptor and thus
platelet aggregation for the platelet’s life span. Fifteen per-
cent of the prodrug gets activated while the remaining 85%
are deactivated by esterases (Scott, Sangkuhl et al 2013). A
wide variety of CYP enzymes contribute to the two-step
bioactivation process of the clopidogrel; however, genetic
studies showed that CYP2C19 mutations have the most
pronounced effect on clopidogrel interindividual
variability.36 The wild-type CYP2C19*1 allele yields func-
tional CYP2C19 enzyme with normal metabolism. Based
on the genetic variants, most common mutations in
CYP2C19 are classified into CYP2C19 no function allele
*2 (c.681G>A; rs4244285); CYP2C19 no function allele *3
(c.636G>A; rs4986893); and CYP2C19*17 gain-of-func-
tion allele (c.-806C>T; rs12248560). While both
CYP2C19*2 and *17 carriers are considered common
among different ethnicities ranging from ~12–35% for *2
and ~3–21% for *17, CYP2C19*3 is very rare among all
populations except Asians where it can reach 10 %. Most of
the PGX studies have found an association between
CYP2C19 genetic variants and response to Clopidogrel.37
The association between CYP2C19 genotype and cardi-
ovascular outcomes in post-ACS and/or post-percutaneous
coronary intervention (PCI) patients was studied in three
main studies.38–40 In TRITON-TIMI 38 trial, carriers of
CYP2C19 no function allele treated with clopidogrel were
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at increased risk of major adverse cardiovascular events
(MACE) (death from cardiovascular causes, myocardial
infarction [MI], or stroke) when compared with noncarriers
(HR 1.53, 95% CI 1.07–2.19, P=0.01) and the risk of stent
thrombosis increased in the CYP2C19 no function allele
carriers (HR 3.09, 95% CI 1.19–8.00, P=0.02).39 In a sub-
sequent study, a secondary analysis was performed to esti-
mate the benefit of prasugrel compared to clopidogrel in
subgroups defined by CYP2C19 genotype, using results
from the published genetic sub-study and the overall
TRITON-TIMI 38 trial.41 Carriers of the no function alleles
had a reduction in the risk of the MACE outcome with
prasugrel when compared to clopidogrel [RR 0.57, 95%
CI 0.39–0.83]. However, there was no significant difference
in the risk of MACE outcome when prasugrel and clopido-
grel were compared in CYP2C19 extensive metabolizers
(RR 0.98; 95% CI 0.80–1.20). Another study that was
conducted by Collet and colleagues in young patients (<45
years) treated with clopidogrel for secondary prevention
after MI found that CYP2C19*2 was the major predictor
of MACE which included death, MI, and urgent coronary
revascularization (HR 3.69, 95% CI 1.69–8.05,
P=0.0005).38 A third study that was conducted by FAST-
MI Investigators suggested that the risk of MACE (death
from any cause, nonfatal stroke, or MI) among clopidogrel-
treated patients with two CYP2C19 no function alleles was
higher than in those with the wild-type allele (HR 1.98, 95%
CI 1.10–3.58).40 In 2009, the first genome-wide association
study with clopidogrel was published and it showed a sig-
nificant association between CYP2C19*2 genotype and
reduced platelet response.42 Additionally, during 1 year of
follow-up, carriers of CYP2C19*2 variant were at higher
risk of cardiovascular ischemic event or death (HR 2.42,
95% CI 1.18–4.99, P=0.02).
As a result of this accumulating evidence, Clinical
Pharmacogenetics Implementation Consortium (CPIC)
published guidelines for CYP2C19 Genotype and
Clopidogrel Therapy. In this guideline, CYP2C19 genotype
was grouped into four main phenotype categories and
recommendations were made accordingly. The categories
are ultrarapid (*1/*17, *17/*17); extensive (*1/*1); inter-
mediate (*1/*2, *1/*3, *2/*17); and poor (*2/*2, *2/*3, *3/
*3) metabolizers.6 Based on the reduced efficacy reported
for both CYP2C19 intermediate and poor metabolizers,
CPIC recommends using an alternative antiplatelet treat-
ment (e.g., prasugrel or ticagrelor) for patients with these
phenotypes.6 FDA, on the other hand, released a “boxed
warning” regarding the CYP2C19 poor metabolizers and
the associated cardiovascular risk but mentioned that rou-
tine testing is not yet recommended.43
One may argue that studying clopidogrel PGX is not
that important, since we can use the more potent P2Y12
blockers (prasugrel and ticagrelor) that are also less likely
to be associated with interpatient variability.44–46
However, studies have shown that clopidogrel is still the
most commonly prescribed antiplatelet.47 This may be due
to its reasonable price which may enhance patient adher-
ence. Additionally, clopidogrel is associated with lower
bleeding risk compared to prasugrel and ticagrelor.48,49
To date, the PHARMCLO trial is the largest trial that
evaluated the bedside genotyping in selecting the appro-
priate antiplatelet therapy (clopidogrel, ticagrelor, or pra-
sugrel) and the associated outcomes in patients with ACS
(majority of which underwent PCI).50 Only 888 partici-
pants were enrolled; then, the study was stopped prema-
turely because of “lack of in vitro diagnosis certification”
for the genotyping instrument (ST Q3). Data from this
study showed a lower risk of the primary outcome (com-
posite of cardiovascular death and nonfatal MI, nonfatal
stroke, and major bleeding) in the genotype-guided arm
versus the standard care. However, the early termination of
the study left it underpowered. IGNITE is another multi-
center observational study that assessed MACE outcome
(death, MI, or stroke) after the implementation of
CYP2C19 genotype-guided approach in selecting the
appropriate antiplatelet therapy after PCI. The study
found that carriers of CYP2C19 no function alleles who
were prescribed clopidogrel versus alternative therapy
were at increased risk of cardiovascular outcomes (HR
2.26, 95% CI 1.18–4.32, P=0.013).19
In addition to clinical studies, several studies assessed
the cost-effectiveness of applying genotype-guided antipla-
telet therapy compared to the universal use of antiplatelet
therapy in patients with MI. Majority of these pharmacoe-
conomic evaluations have shown that implementing geno-
type-guided antiplatelet therapy, followed by a targeted
administration of the expensive ticagrelor or prasugrel in
CYP2C19 no function allele carriers and clopidogrel in
noncarriers is the most cost-effective approach compared
to the universal use of antiplatelets.51–54
However, powered randomized clinical trials are still
needed to determine the effectiveness of routine CYP2C19
genetic testing for clopidogrel therapy in ACS patients.
Currently, there are two ongoing clinical trials to address
this need which are TAILOR-PCI and the POPular
Genetics study.55,56
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Warfarin
For more than half a century, warfarin has been the corner-
stone oral anticoagulant medication used in the treatment
and prevention of various thromboembolic conditions.57
Warfarin is a vitamin K antagonist that inhibits the vitamin
K cycle by binding to the oxidized vitamin K epoxide
reductase (VKOR) and prevents the reduction of vitamin
K.58,59 Reduced vitamin K is essential for the activation of
the coagulation factors (II, VII, IX, and X), in addition to
proteins C and S. Consequently, coagulation factors with
impaired activity are produced in the liver which leads to a
state of anticoagulation. Warfarin is administered as a race-
mic mixture of two enantiomers (R and S) in almost equal
proportions. The S isomer is mainly metabolized by the
cytochrome P450 family 2 subfamily C polypeptide 9
(CYP2C9) and it is five times more potent than the R isomer
but has faster clearance.60 Among the most important draw-
backs of warfarin is its narrow therapeutic index which can
mediate serious bleeding adverse events that can even lead
to hospitalization and death.61,62 Another disadvantage is
the inter- and intra-patient variability in the dose required to
achieve the optimal anticoagulation response. Dose require-
ments can vary from 0.5 mg to 20 mg per day.63 Various
studies showed that genetic and nongenetic factors contri-
bute to warfarin dose variability.64–66 The most important
genes affecting warfarin dose among different populations
are the CYP2C9 – a gene that codes for CYP2C9 enzyme
which metabolizes and eliminates the more potent S enan-
tiomer of warfarin, and VKORC1 – a gene that codes for the
VKOR which is the enzyme inhibited by warfarin.64,65
CYP4F2, an enzyme that metabolizes vitamin K, has also
mutations in the gene coding for its enzyme that may play a
role in warfarin dose variability but to a limited extent and
not consistent among all populations.67,68 As such, the FDA
updated the drug label for warfarin with PGX information
in 2007.69
In 2009, the International Warfarin Pharmacogenetics
Consortium reported that the PGX algorithm they developed
from clinical characteristics (warfarin indication, target inter-
national normalized ratio [INR], height, and weight), demo-
graphic characteristics (gender, age, and concurrent
medications), and genetic information of over 4000 patients
has helped to create a dosing algorithm for estimating the
appropriate initial dose of warfarin. In this algorithm, the
presence of the following led to reduction in the maintenance
warfarin dose: VKORC1 polymorphism (1639/3673G>A by
28% per allele, CYP2C9*3 by 33% per allele, CYP2C9*2 by
19% per allele), the age by 7% per decade, amiodarone use
by 22%, and race by 9% for African American race. On the
other hand, the presence of the following increased the
required maintenance dose: body surface area by +11% per
0.25 m2, target INR by 11% per 0.5 unit increase, smoker
status by 10%, and current thrombosis by 7%. This study
concluded that algorithms incorporating genetic variants
(CYP2C9 and VKORC1) can improve dose prediction com-
pared with algorithms based solely on clinical and demo-
graphic factors.70
The Clarification of Optimal Anticoagulation through
Genetics (COAG) and the European Pharmacogenetics of
Anticoagulant Therapy (EU-PACT) are two landmark
trials that aimed to evaluate the utility of warfarin geno-
type-guided dosing.71,72 Results from both trials were not
consistent with each other. COAG trial showed no benefit
of genetic-guided dosing, compared to clinical dosing
while EUPACT did. Furthermore, COAG found that the
percent time in therapeutic range (PTTR) was significantly
lower in blacks in the genetic-guided arm compared to the
clinical dosing arm.71 This is possibly due to the fact that
blacks may have other less common variants affecting
warfarin dose that were not well represented in the genetic
algorithm used in the COAG trial.73 The EU-PACT study,
on the other hand, compared PGX-based dosing versus
fixed-dose strategy and was performed in a predominantly
white population from Europe.72 Recently, a third land-
mark trial – Genetics-InFormatics Trial (GIFT) – also
tested the utility of warfarin pharmacogenetic-guided
dosing.74 The PGX dosing algorithm used included geno-
types for CYP2C9*2 and *3, CYP4F2*3, and VKORC1-
1639. The primary endpoint was a composite of major
bleeding, INR ≥ 4, venous thromboembolism, or death.
GIFT indicated that genotype-guided dosing could
improve the composite outcome of efficacy and safety.
Of the participants, 10.8% had at least one composite
endpoint in the genotype-guided arm, compared to 14.7%
in the clinical arm, resulting in an absolute risk difference
of 3.9% (95% CI, 0.7–7.2; P=0.02). There was also an
improvement in the mean PTTR (54.7% vs 51.3%,
P=0.003) in the genotype-guided group compared to the
clinical group.
While the performance of genetic testing prior to war-
farin initiation is not recommended in evidence-based
practice guidelines, it may be worth considering to use
genetic data if available prior to warfarin initiation.63
Guidance on the exact algorithm to use and race-specific
recommendations are provided through different PGX
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working groups.75,76 Another important aspect is the
increasing use of direct oral anticoagulants (DOACs) as
a replacement for warfarin. However, due to cost, contra-
indications (major renal impairment), and harm, when
used for certain indications (valvular replacement, anti-
phospholipid antibody syndrome), warfarin is still consid-
ered a very important option when choosing an oral
anticoagulant. As such, genetics may be used as a guide
to choose warfarin versus DOACs in addition to its use to
tailor warfarin dosing. Patients with high-risk genotypes
(carriers of variants associated with very low or very high
warfarin dose) may benefit from DOACs in a cost-effec-
tive way. This, however, remains to be tested.
Future And Challenges Of
Pharmacogenomics
It is well documented in the literature that the application of
pharmacogenomics in clinical practice has resulted in
improving the efficacy and minimizing the untoward effects
of several drugs. A recent paper has provided an overview of
the evolution of pharmacogenomics in clinical pharmacy
practice and the advancement of its implementation, educa-
tion, and research (Hicks, Aquilante, Dunnenberger et al
2019).25 The authors believe that future implementation
models of pharmacogenomics and precision pharmacother-
apy will include the integration of the “omics” (epigenomics,
transcriptomics, proteomics, and metabolomics) informa-
tion. Undoubtedly, these advances will require health infor-
mation technology (i.e., health informatics) solutions and
effective EHR systems.27 With the revolution in whole-gen-
ome sequencing and tremendous drop in its cost, genetic data
are expected to be present at the tip of our fingers. Data
storage, quality checking, mapping and integration with
EHRs remain the biggest challenges. In addition, ethical,
legal, and social concerns should be taken very seriously to
avoid any discrimination against individuals based on their
DNA. With increasing recognition of the value of precision
pharmacotherapy and its implementation in many practice
settings, more outcome-based studies are needed in order to
quantify the impact on health outcomes. Furthermore,
advanced pharmacist functions in applying pharmacoge-
nomics in clinical practice may require specialized
education, training, and relevant experiences.77,78More phar-
macogenomic courses and content are likely to be seen in the
curricula of colleges of pharmacy and certification programs
globally.77,78 Given the need for infrastructure, resources,
and capacity building, the application and implementation
of PGX in clinical practice may be slow in resource-con-
strained environments.
Conclusion
Pharmacists can and should play an integral role in apply-
ing PGX into clinical practice to improve both the quality
and safety of health care.
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